Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
- The Art of Business
September 26, 2011
- Chugai Licenses Melanoma Treatment Vemurafenib from Roche; PI Trial to Begin in 2012
August 29, 2011
- Pfizer Japan Withdraws NDA for Fesoterodine
August 29, 2011
- Switch OTC Versions of Pemirolast K Recommended for Approval
August 29, 2011
- BI Licenses ADCC Enhancing Technology from ProBioGen
August 29, 2011
- Caffeine Citrate Designated as an Orphan Drug
August 29, 2011
- JAMS Opposes Switch OTC Status for 3 Drugs Including Acarbose
August 29, 2011
- Eisai Establishes Marketing Subsidiary in Mexico
August 29, 2011
- JGA to Ask for Retention of “70% Rule”in Pricing of “First Generics”
August 29, 2011
- Mr Wolf of PhRMA Explains Advantages of VICP Introduced in US
August 29, 2011
- Shionogi Acquires 24.17% Stake in C&O of China
August 29, 2011
- Kyowa Pharm. Ind. Seeking M&A to Expand Product Line-up
August 29, 2011
- Saitama Police Send Case to Public Prosecutors Office against President of Saitama Pharm. Association
August 29, 2011
- US Court Orders Actelion to Pay Damages to Asahi Kasei Pharma for Stopping Fasudil's Development
August 29, 2011
- Biosimilars Offer Growth Opportunity: President Sakamoto of Toyobo
August 29, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…